MOR MorphoSys
- 17.335
- -0.705-3.91%
MorphoSys News
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment.Myelofibrosis is a type of blood cancer characterized by the
MorphoSys AG Announces Major Shareholder Update
Impacted by reports of drug safety issues, Morphosys (MOR.US) says the Novartis Pharmaceuticals (NVS.US) acquisition will continue as planned
The Zhitong Finance App learned that on Monday, the stock price of German biotech company Morphosys (MOR.US) fell due to a news report about its drugs or safety risks, but Morphosys said that Novartis Pharmaceuticals (NVS.US) is still expected to complete its acquisition in the first half of this year. Prior to Morphosys' statement, the professional website StatNews quoted two people familiar with the matter as reporting that the company is developing an experimental drug pelabresib to treat myelofibrosis (a rare type of blood cancer affecting bone marrow)
New Safety Risk for MorphoSys Drug Could Complicate Novartis Deal - STAT
A new safety risk related to Morphosys's (NASDAQ:MOR) pelabresib, an experimental treatment for myelofibrosis, could complicate the company's planned $3B sale to Novartis (NYSE:NVS).
MorphoSys AG Announces Shift in Major Holdings
MorphoSys AG Sees Shift in Major Shareholders
MorphoSys AG Unveils Cancer Drug Trial Progress
MorphoSys AG Shares Shift in Major Holdings
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Tuesday, Incyte Corporation (NASDAQ:INCY) agreed to acquire Escient Pharmaceuticals for $750 million.Escient's pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled rec
Morgan Stanley Adjusts Stake in MorphoSys AG
MorphoSys AG Reports Change in Major Holdings
MorphoSys AG Reports Shift in Voting Rights
MorphoSys Shareholding Shift With Barclays' Increased Stake
MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per Share
On 11 April 2024, Novartis BidCo, Basel, Switzerland, ("Bidder") has published the offer document regarding its takeover offer (cash offer) to the shareholders of MorphoSys AG, Planegg, Germany ("Morp
MorphoSys AG Reports Major Norwegian Stake
Trending: Novartis Begins Tender Offer for MorphoSys Shares
1535 ET -- MorphoSys is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Novartis began its tender offer for MorphoSys shares, wit
MorphoSys and Novartis Maintain Expectation Closing of Takeover Offer Be in 1H >MOR
MorphoSys and Novartis Maintain Expectation Closing of Takeover Offer Be in 1H >MOR
MorphoSys: Acceptance Period Has Commenced and Will End on May 13 >MOR
MorphoSys: Acceptance Period Has Commenced and Will End on May 13 >MOR
MorphoSys: Novartis Offers EUR 68.00 Per Shr in Cash, Representing Total Equity Value of EUR 2.7 B >MOR
MorphoSys: Novartis Offers EUR 68.00 Per Shr in Cash, Representing Total Equity Value of EUR 2.7 B >MOR
Analysis
Price Target
No Data
